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Abstract
Background: In Hong Kong, thalassemia major (TM) patients utilized up to 9.5% of blood supply in 2009. For long-term
management of blood supply, we predicted the future blood demand of TM patients for the next 10 years.
Methods and Results: Annual individual transfusion data in 2005–2009 and demographic information of 381 TM patients
were obtained from the Hong Kong Red Cross Blood Transfusion Service database. A generalized estimating equation (GEE)
model was fitted to establish the potential relations of blood demand with age, sex, body weight, year of transfusion and
splenectomy, accounted for within-patient correlation. The fitted model was used to predict future blood demand for the
existing patients by accounting for expected change in body weight and mortality rate. We also predicted the number of
new cases in the future based on age- and sex-specific TM incidence and official population projections. Future blood
demand was predicted by combining blood demand from the existing and new patients. Female (RR = 0.94, p = 0.006) and
history of splenectomy (RR = 0.85, p,0.001) were significantly associated with lower blood demand, while age and weight
had an inverted U-shape relation with maximal blood demand at around 24 years of age and 71.8 kg, respectively. We
predicted that the total blood demand would increase 0.81% annually from 13,459 units in 2009 to 15,183 units in 2024,
with new TM cases accounting for 31.7% of the overall blood demand in 2024.
Conclusions: Our results showed that future annual blood demand from TM patients would steadily increase in the next 10
years. Reducing incidence of TM cases in the future (by improving public education, antenatal care, prenatal diagnosis) and
minimizing blood use among existing TM cases (e.g. with hemopoietic stem cell transplantation) can help relieve the
burden on management of future blood demand.
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Introduction
Blood demand has been increasing all over the world. Ageing of
the population worldwide [1] together with higher cancer
incidence in advanced ages is a major reason for increased blood
utilization [2]. Life expectancy of both healthy and diseased people
are expected to increase with continual advances in medical care
and technologies. However, as more people survive longer, they
are more likely to develop chronic illnesses and degenerative
problems, thereby increasing blood demand. Although these
patients may not be cured, medical management and blood
transfusion allow them to survive longer (with some achieving close
to normal life expectancy) but at the expense of large amount of
blood use.
Hong Kong has a population of about 7 million with an annual
blood supply of 226,718 units in the financial year 2010/11 [3].
All blood donation services, from collection to distribution, are
managed by the Hong Kong Red Cross Blood Transfusion Service
which is part of the Hong Kong Hospital Authority. Over the
years, Thalassemia Major (TM) patients have been shown to use
increasingly more blood and with less than 400 cases, they utilize
up to 9.5% of annual blood supply in Hong Kong [4]. With good
antenatal care, the number of new TM cases is not expected to
increase significantly. However, with continual advances in
medicine, particularly blood transfusion and iron chelating
therapy, the survival of TM patients has been and will be
substantially prolonged, as similarly observed among those
patients with aplastic anemia [5]. This will increase not only the
associated health care cost, but more importantly, have direct
implication in the provision of blood supply. Hong Kong has a
rapidly ageing population which requires more blood transfusion
and also ageing of first time blood donors at the same time [6]. A
large effort has been invested in the recruitment of new donors as
well as retention of existing donors to maintain stable and
sufficient blood supply [7]. Hence, prediction of blood demand
from this group is important for long-term management of blood
supply. In this paper, we aimed to predict the blood demand of
TM patients in Hong Kong in the next 10 years in order to allow
better planning of blood services. Methods for prediction of blood
demand have been employed for emergency medicine and surgery
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[8,9,10] or at a population level [11,12], but no studies have
looked into future blood demand from patients who require
chronic transfusion. Here we proposed a practical statistical model
which takes into account the impact of future growth in body
weight of TM patients and nonlinear effects of age on blood
demand from this group in the future.
Methods
We retrospectively examined transfusion request records of all
TM patients who required chronic blood transfusion in public
hospitals of Hong Kong between 1 January 2005 and 31
December 2009. All public hospitals in Hong Kong are managed
by the Hong Kong Hospital Authority and these records
accounted for essentially all blood demands from TM patients in
Hong Kong during this period. Annual blood demand for each
patient was recorded along with patient information on sex, age,
body weight and history of splenectomy by 2009. Survival rate of
TM patients has improved significantly during the last decade
because of recent medical advances and patient management [13].
As such, only the death counts in 2005–2009 were used to predict
future mortality of TM patients though data from earlier periods
were available [4].
Prediction of Blood Demand from Existing Patients
We fitted a Poisson generalized estimating equations (GEE)
model [14] for above-mentioned blood demand (the outcome
variable) to establish the potential relation of blood demand from
TM patients with age, sex, body weight, years of transfusion and
history of splenectomy. All patients who had irregular blood
transfusion (e.g. those who submitted transfusion request every
other year) and incomplete records were excluded. Blood
transfusion records for patients younger than 12 months were
not used in the prediction model because TM patients typically
start requiring blood transfusion therapy any time between 6 and
12 months of age. Past body weights in 2005–2008 were imputed
based on the US CDC growth curve (details below).
The Poisson GEE model was chosen in order to account for the
correlation between different episodes of blood demand from the
same TM patient and potential overdispersion of the data by using
the robust sandwich estimator for the variances [15]. We selected
the potential predictors and appropriate correlation structure by
the leave-one-out cross-validation method [16], where the
predictive performance of the model was evaluated by iteratively
fitting the model using all but one observations, and the predicted
values were compared against the observations being left out. In
the base model we included known important predictors of blood
demand such as age, sex, body weight and history of splenectomy
[17,18], while other model variants including combinations of
predictors such as years of transfusion and quadratic terms of
weight and age were compared. We aim at developing a simple
and practical model to predict long term blood at the population
level including most important predictors [17,18] and potentially
important interaction effects particularly with age or weight. Mean
absolute prediction error (MAE) between predicted and observed
blood demand in the validation dataset was used to assess the
predictive performance of the models.
The selected model was used to predict future blood demand for
each patient accounting for expected changes in body weight in
the future among adolescents and children. More specifically, we
transformed the weight of each TM patient into z-scores using the
LMS method [19], and used the CDC growth curve [20] to
project future weight assuming that the z-score of each patient
remained constant. For patients with missing body weight, we
imputed their expected weight using the mean z-score in the same
age group. We assumed body growth was negligible after the age
of 20. Blood demands in 2010–2024 of the existing TM patients
were predicted based on the fitted model and projected weights.
Prediction of Blood Demand from New Cases
Future blood demand was calculated as the sum of demands
from both existing TM patients and new cases of TM patients in
the future. We estimated the number of new TM cases by
assuming that age- and sex- specific incidence rate of TM in 2010–
2024 would be the same as in the 2006–2009 data. These
incidence rates were then applied to the projected population in
2010–2024 made by the Census and Statistics Department [21].
We stratified patients by sex and by age groups 0–4, 5–9, 10–19
and 20–59 years respectively. Assuming the new TM cases had
similar blood demand characteristics as existing cases, we
predicted their future blood demand based on the fitted Poisson
GEE model using the group means for the explanatory variables.
Prediction intervals were calculated by the delta method [22]
Table 1. Mean absolute prediction error of the predicted
blood demand under different model variants by leave-one-
out cross-validation.
Correlation structure
Model variant Independent Exchangeable
Base model* 6.814 6.827
+ age2 6.002 6.040
+ weight2 6.058 6.112
+ year of transfusion 6.814 6.821
+ age2, weight2 5.792 5.830
+ age2, year of transfusion 5.997 6.026
+ weight2, year of transfusion 6.063 6.103
+ age2, weight2, year of transfusion 5.787 5.810
*include predictors sex, history of splenectomy, linear effects of age and weight
only.
doi:10.1371/journal.pone.0081846.t001
Table 2. Associations between blood demand and age,
weight, sex and history of splenectomy using Poisson
generalized estimating equations model, with the associated
95% CI, and p-values.
Variables
Relative blood
demand* 95% CI{ P-value
Age 1.04 (1.02, 1.05) ,0.001
Age2 0.9992 (0.9989, 0.9995) ,0.001
Weight 1.04 (1.03, 1.05) ,0.001
Weight2 0.9997 (0.9996, 0.9998) ,0.001
Female 0.94 (0.91, 0.98) 0.006
Splenectomy 0.85 (0.81, 0.89) ,0.001
CI confidence Interval.
*mutually adjusted for age, weight, sex and history of splenectomy.
{the estimated scale parameter was 1.71 which indicated moderate
overdispersion. The sandwich estimator for the standard errors were used to
construct the 95% CIs.
doi:10.1371/journal.pone.0081846.t002
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which accounted for uncertainties in the estimated blood demand
from the GEE model and the forecast error in the population
projections.
We also calculated the annual mortality rate of TM patients
based on the death counts in 2005–2009. As patients younger than
20 years had high survival rate and there are limited recent data
on the long-term survival rate [23,24], we applied a constant
mortality rate to patients aged 20 years or above and adjusted the
predicted blood demand by deducting blood usage from the death
cases. All analyses were implemented in R version 2.15.2 [25].
Details of the prediction methods were described in Text S1.
Results
There were a total of 381 TM patients in the dataset with 189
(49.6%) males and 192 (50.4%) females. Age ranged from 3
months to 56 years with a median of 23 years. Mean body weight
was 46.5 kg and 138 (36.2%) of the patients had undergone
splenectomy.
338 patients were included in the Poisson GEE model. 31
patients (8.1%) and 12 patients (3.1%) were excluded due to
irregular blood transfusion records and missing records of body
weights, respectively. Mean annual blood demand of these patients
who required regular transfusion was 38.7 units. We found that
there was little multicollinearity between predictors as all variance
inflation factors (VIF) were below 3 for all predictors. Among all
the model variants, the best model included sex, quadratic effects
of age and weight, year of transfusion and history of splenectomy
as predictors for blood demand, with an independent correlation
structure (zero within-patient correlation between blood demand
at different years), with a minimum MAE of 5.787 (Table 1).
Considering that models including quadratic effects of age and
weights performed markedly better but those models including
year of transfusion only negligibly improved the predictive power,
we excluded the predictor year of transfusion in our final
Figure 1. Estimated effects of age and weight on blood demand, based on the fitted Poisson generalized estimating equations
model.
doi:10.1371/journal.pone.0081846.g001
Figure 2. Predicted blood demand and prediction intervals of Thalamessia Major patients, 2010–2024. Crosses show the actual
blood demand in 2005–2009.
doi:10.1371/journal.pone.0081846.g002
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predictive model. For the same reason, we did not include
interaction terms which only improved the predictive power
slightly to a MAE of 5.767 (Table S1).
Table 2 shows the estimated effect of the predictors on blood
demand. Age and weight were found to have an inverted U-shape
relation with blood demand with a maximum demand at age 23.7
years and 71.8 kg respectively (Figure 1). Blood demand also
increased with body weight but at a slower rate for those with
higher body weight. Females and those who had undergone
splenectomy had 5.6% and 15.4% less blood demand. No
significant time trend in blood transfusion demand was found.
Total blood demand in existing TM patients increased 1.9%
annually from 12,469 units in 2005 to 13459 units in 2009. Based
on the fitted GEE model, we predicted that blood demand from
existing TM patients would decrease to 10,363 units (95%
prediction interval PI = 10,067 to 10,658) in 2024 (Figure 2). We
estimated that the annual incidence of TM cases requiring chronic
transfusion was 0.13/100,000 (95% CI= 0.06 to 0.24/100,000),
which translated to about 9–10 new TM cases every year in year
2010–2024. The annual mortality rate was estimated to be 0.96%
(95% CI= 0.78% to 1.13%). By including these new patients and
accounted for the death cases, the total blood demand was
predicted to increase 0.81% annually to 15,183 units (95%
PI= 14,787 to 15,579) in 2024 with new cases accounting for
31.7% of the overall TM blood demand in 2024. As sensitivity
analyses, assuming the mortality rate in TM patients reduced
linearly by a further 40% or 80% in the next 10 years [4], the total
blood demand was predicted to increase 0.95% or 1.21% annually
to 15,656 units (PI = 15,261 to 16,052) or 16,129 units (95%
PI= 15,734 to 16,525) respectively in 2024.
Discussion
Future Blood Demand by Thalassemia Major Patients
By considering important factors for predicting blood demand,
in particular, expected changes in body weight of TM patients and
age as a proxy of physical activity, we provided a realistic
prediction of blood demand of TM patients in Hong Kong in the
next 10 years. We predicted that future demand of blood
transfusion from TM patients would increase at a rate of 0.81%
annually, lower than the rate of 1.9% in 2005–2009. The annual
population growth in Hong Kong for the same period has been
projected to be 0.9% [21]. Our prediction took into account
changes in demographic structure and expected new cases of TM
patients requiring chronic blood transfusion. Currently, the
combined effect of low fertility rate in Hong Kong (total fertility
rate = 1.1) [26] and better survival of TM patients [4] results in a
slower rate of increase in blood demand from these patients. Our
predicted annual increase of blood demand from TM patients is
lower than the expected increase of 2–3% in overall blood
demand, even with significant improvement in survival [27].
However, with moderate improvement in the survival of TM
patients, the growth of overall blood demand is expected to rise
faster than population growth, which suggests that management of
blood demand from TM patients is still important.
In the last decade, there has been a rapid increase in the
proportion of births by women from mainland China (from 15.9%
in 2001 to 46.1% in 2010), many of whom came from Guangdong
province [28]. Hong Kong and Guangdong province have similar
prevalence of beta-thalassemia carriage [29,30], though regular
transfusion therapy may not be always available for TM patients
in Guangdong [31]. More recently, there has been upsurges of
non-local obstetric patients who are not eligible for obstetric
services at government subsidized rate and have had late or no
antenatal screening before they gave birth in Hong Kong [32].
These patients are associated with late presentations of blood
disease such as fetal haemoglobin Bart’s disease which may require
intrauterine blood transfusion [33]. The children have full
residency rights to enjoy medical services in Hong Kong and
may disproportionately increase patients who need chronic
transfusion therapy in the future.
Our proposed model utilized commonly available sources such
as basic patient information and official population projection to
predict future blood demand from TM patients, which can be
easily applied to other populations with minor modification. In
Hong Kong, TM incidence is likely to be stable due to well
established antenatal care program and our results showed that
blood transfusion from new TM cases will not increase total blood
demand rapidly. In populations with increasing antenatal care
coverage, the expected reduction in TM incidence should be
accounted for in the prediction model. Potential benefits of
improving antenatal coverage on blood usage can be assessed for
better distribution and long-term management of blood demand.
Though our study has compared different model variants for
more accurate prediction of blood demand in TM patients, there
are several limitations worth noting. We showed that inclusion of
the nonlinear effects of age and weight significantly improved the
prediction of blood demand though our dataset covered only 5
years of data and did not allow comparison of prediction accuracy
of different models over a longer period. Another limitation was
that the time of splenectomy was not available in the dataset.
While splenectomy is negatively associated with blood demand,
our model assumed a constant status and might have underesti-
mated the effect of splenectomy on the reduction of blood
demand. However, in our dataset there were less than 40% of the
TM patients who have ever undergone splenectomy, it has been
estimated that only less than 10% of TM patients had undergone
splenectomy in 2006–2009. As such, its impact on our estimates
should be limited. Although the cross-sectional nature of our
analysis does not provide strong evidence to establish a causal
relation between blood demand reduction and splenectomy, other
studies have demonstrated a similar relation [17,18]. While
projected changes in blood demand from existing TM patients
has been considered in our analysis, our prediction of blood
demand from new TM cases would be sensitive to changes in TM
incidence or demographic trends not reflected in the population
projection made by the Census and Statistics Department in Hong
Kong, such as new trends in fertility rate or cross-border deliveries,
or breakthrough in the treatment of TM which may reduce
transfusion requirement. Also, for practical reasons, detailed
clinical data were not used in the planning of blood demand
and the model may leave out potential confounders.
In conclusion, our results show that future annual blood
demand from TM patients who require regular blood transfusion
will increase by 12.8% from 13,459 units in 2009 to 15,183 units
in 2024. Reducing incidence of new TM cases through public
education, antenatal care, prenatal diagnosis, along with mini-
mizing blood use in existing cases with hemopoietic stem cell
transplantation, may help improve long-term management of
future blood demand in Hong Kong.
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